Karyopharm Therapeutics Inc (KPTI)

9.78
0.17 1.70
NASDAQ : Health Care
Prev Close 9.95
Open 9.96
Day Low/High 9.62 / 10.04
52 Wk Low/High 4.83 / 23.59
Volume 135.37K
Avg Volume 358.40K
Exchange NASDAQ
Shares Outstanding 47.12M
Market Cap 461.76M
EPS -2.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Karyopharm To Report First Quarter 2017 Financial Results On May 4, 2017

Karyopharm To Report First Quarter 2017 Financial Results On May 4, 2017

Conference Call Scheduled for Thursday, May 4, 2017 at 8:30 a.m. ET

Commit To Purchase Karyopharm Therapeutics At $7.50, Earn 15% Annualized Using Options

Commit To Purchase Karyopharm Therapeutics At $7.50, Earn 15% Annualized Using Options

Investors eyeing a purchase of Karyopharm Therapeutics Inc stock, but tentative about paying the going market price of $11.72/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at the $7.50 strike, which has a bid at the time of this writing of 65 cents.

Six Stocks Spiking Up With Huge Volume

Six Stocks Spiking Up With Huge Volume

Here's a technical look at how to play six stocks trending higher with strong volume.

Short Interest Makes 14.6% Move For KPTI

Short Interest Makes 14.6% Move For KPTI

The most recent short interest data has been released for the 03/31/2017 settlement date, which shows a 316,239 share increase in total short interest for Karyopharm Therapeutics Inc , to 2,483,391, an increase of 14.59% since 03/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Karyopharm And Medidata Expand Clinical Trial Partnership

Karyopharm And Medidata Expand Clinical Trial Partnership

Medidata (NASDAQ:MDSO) and clinical-stage pharmaceutical company Karyopharm Therapeutics (NASDAQ:KPTI) today announced an expanded partnership to bring novel machine-learning technology and targeted risk-based monitoring...

Karyopharm To Report Fourth Quarter And Year End 2016 Financial Results On March 16, 2017

Karyopharm To Report Fourth Quarter And Year End 2016 Financial Results On March 16, 2017

Conference Call Scheduled for Thursday, March 16, 2017 at 8:30 a.m. ET

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Karyopharm Therapeutics falls 18%; Lexicon rises on drug approval.

Commit To Buy Karyopharm Therapeutics At $7.50, Earn 19.6% Annualized Using Options

Commit To Buy Karyopharm Therapeutics At $7.50, Earn 19.6% Annualized Using Options

Investors eyeing a purchase of Karyopharm Therapeutics Inc stock, but tentative about paying the going market price of $10.05/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $7.50 strike, which has a bid at the time of this writing of 85 cents.

Short Interest Jumps 19.7% For KPTI

Short Interest Jumps 19.7% For KPTI

The most recent short interest data has been released for the 12/30/2016 settlement date, which shows a 289,025 share increase in total short interest for Karyopharm Therapeutics Inc , to 1,756,850, an increase of 19.69% since 12/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.